Boy's life saved after 'death sentence' disease
Summary
A young boy named Eisa, born with a severe form of an ultra-rare immune disease called leukocyte adhesion deficiency 1 (LAD-1), is now leading a normal life thanks to a pioneering gene therapy trial. This treatment helped Eisa's immune system to fight infections effectively.Key Facts
- Eisa, a four-year-old boy from Reading, was born with leukocyte adhesion deficiency 1 (LAD-1), a rare and typically fatal immune disorder.
- He participated in a groundbreaking trial for a new form of gene therapy.
- The gene therapy treatment manipulates the patient's own cells to produce a missing protein, enabling the body to fight infections.
- The treatment was administered when Eisa was 10 months old, and he can now play football and attend school.
- His father, Safdar, praised the treatment for exceeding his expectations.
- The treatment was facilitated by Great Ormond Street Hospital.
- The success of this trial could lead to the use of gene therapy in treating various other conditions, including cancer and muscular dystrophy.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
